maker of tirzepatide Safety Risks: FDA Recall Urged | Chemist+Druggist posted on the topic Weight-loss drug Zepbound now in

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

Regular follow-up with your healthcare team allows for ongoing assessment and adjustment of your treatment plan

ALSO ON RAPPLER What are the PH Maritime Zones Act, Archipelagic Sea Lanes Act all about

The Nomenclature Committee on Cell Death (NCCD) classifies cell death into two broad categories based on functional and mechanistic criteria: accidental cell death (ACD), a passive process, and regulated cell death (RCD), an active, gene-controlled mechanism ( Ferroptosis, first identified and described by Dixon et al